Introduction
International groups of investigators have synthesized during the decade over a thousand analogs of the luteinizing hormone releasing hormone (LHRH) toward the achievement of antagonists which would have high potency and effective duration of action for the control of conception. Three investigations are cited to exemplify current progress toward the goal.
Coy et al. [1] reported on the -"unexpectedly favorable outcome" -of introducing D-Lys 6 and D-Arg 6 Rivier et al. [2] found that combinations of D-Trp and/or /?-(2-naphthyl)-D-a-alanine in positions 3 and/or 6 resulted in increases of antiovulatory potency in certain analogs.
Folkers et al. [3] reported on the introduction of pyridylalanines into analogs of LHRH for antagonists, and found that one such analog completely inhibited ovulation at a nanogram dosage. This + Reprint requests should be sent to Dr. Karl Folkers. 0340-5087/83/1000-1253/$ 01.00/0 analog is [N-Ac-D-2-Nal 1 , ^Cl-D-Phe 2 , D-3-Pal 3 , D-Arg 6 , D-Ala 10 ]-LHRH, which caused 100% and 57% inhibition of ovulation in rats, s.c., at 500 and 250 ng, respectively. This analog also showed 56% inhibition, per os, at 500 /ug.
A diversity of antagonists of LHRH having D-tryptophan in position 3 and/or 6 have been extensively investigated and found effective, and analogs having a naphthylalanine have also been found to be effective antagonists. The bicyclic nature of the indole and naphthalene nucleus with and without a nitrogen atom was a basis for our synthesis of D-heterocyclic analogs of tryptophan and naphthylalanine, and insertion of these heterocyclic amino acids into the most favorable sequences of known antagonists for antiovulatory activity. Quinolylalanines (Qal-) and pyridylalanines (Pal-) were initially synthesized, because these amino acids combine basicity, aromaticity and hydrophilicity in the same molecule. We report the synthesis and bioassay data of analogs of LHRH which have D-3-Qal in various combinations with D-3-Pal, D-Trp and D-Arg in positions 3 and/or 6.
Materials and Methods
Amino acid derivatives were purchased from Peninsula Labs, San Carlos, CA. The a-amino functions were protected by the BOC-group, except for L-arginine which had the AOC-group. Side-chain functions were protected by the benzyl group for serine, the tosyl group for arginine and histidine and the o-bromocarbobenzoxy group for tyrosine. BOC-)-chloro-D-phenylalanine and 3,4-dehydro-L-proline were provided by the Southwest Foundation for Research and Education, San Antonio, TX. p-Fluoro-DL-phenylalanine was obtained from the Sigma Chemical Company and the methyl ester was enzymatically resolved [4] .
We synthesized /3-(3-quinolyl)-D-a-alanine and /3-(3-pyridyl)-D-a-alanine as their dihydrochlorides [5] . BOC derivatives of 3,4-dehydro-L-proline, ^-fluoro-D-phenylalanine, and ß-(3-quinolyl)-D-aalanine were obtained by using the procedure of Moroder et al. [3, 6] . The benzhydrylamine resin hydrochloride was obtained from Beckman Bioproducts, Palo Alto, California. DCC, triethylamine and the solvents were distilled prior to use. All other chemicals were of reagent or analytical grade.
Peptides. The analogs were synthesized by solidphase method as described [7] . Purification of the crude peptides was achieved by an appropriate choice of sequences from the following methods: (A) gel filtration over Sephadex G-25 in 20% acetic acid; (B) chromatography over silica gel 60 (230 to 400 mesh) in n-butanol-acetic acid-water, 4:1:5 upper phase; (C) semipreparative high pressure liquid chromatography on a /^-Bondapak Cis column in linear gradients of buffer A (0.05 M ammonium acetate, pH 5.0), and buffer B (20% buffer A/80% acetonitrile). The methods of purification of each peptide are in Table II . The homogeneity of the peptides was examined by TLC on silica gel in four solvent systems [3] . HPLC was the ultimate criterion for the purity of the peptides. The equipment of Waters Associates, Milford, MS, with a gradient programmer and /^-Bondapak Cis reversed phase column (30 cm) were used. The solvent system was buffer A (0.01 M KH2P04, pH 3.0) and buffer B (50% buffer A/50% acetonitrile, v/v). The linear gradient was 40-100% B in 20 min; the flow rate was 2.0 ml/min; and monitoring was at 210 nm. The retention times on HPLC are in Table II . Amino acid analyses were carried out on a Beckman 118CL automatic amino acid analyzer, Palo Alto, CA, which was equipped with a Hewlett Packard, Palo Alto, CA, 3390 A integrator, after hydrolyzing the peptides in constant boiling HCl with phenol. The amino acid compositions are in Table II . The peptides were assayed for their degree of activity to inhibit ovulation in rats, as described [8] .
Results and Discussion

Chemical aspects
A small sample of /?-(3-quinolyl)-DL-a-alanine was kindly provided by Dr. Elizabeth Dyer, University of Delaware. Dyer and Yokohama [9] synthesized this compound. This sample was used to synthesize [N-Ac-3 zl Pro 1 , j9F-D-Phe 2 , D-Trp 3 , DL-3-Qal 6 ]-LHRH (I). The two isomers of this analog (I) were separated by silica gel column chromatography. One isomer showed 100% antiovulatory activity at a dosage of 6 /zg/rat; the other isomer was inactive at this dosage. It was assumed that the isomer having antiovulatory activity had the D-3-Qal 6 -moiety, because other antagonists generally had a D-substituent in position 6. When ^-(3-quinolyl)-D-a-alanine was synthesized [5] , it was used for repetition of the synthesis of analog I, and this analog showed antiovulatory activity of 40% at 3 jug, and 80-100% at 6 jxg per rat, respectively; Table I . Therefore, the active isomer from the mixture having the DL-3-Qal 6 -moieties had been correctly identified as having D-3-Qal 6 -on the basis of biological activity and the relative inactivity of the other isomer. The strategy of synthesizing a pair of isomeric peptides from the use of a DL-amino acid followed by bioassay of the separated isomers avoids the necessity of an initial resolution of the DL-amino acid, which is being introduced for possible improvement of activity. Resolution may be reserved for the most promising analogs on the basis of antiovulatory activity.
[N-Ac- 3 [3] .
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